Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Cammie Lesser
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Synlogic
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Lesser has a financial interest in Synlogic, a privately held company developing technologies related to using synthetic biotics to effect metabolic functions for disease treatment throughout the body. Dr. Lesser has been paid for consulting by this entity. This research proposal focuses on engineering bacteria to carry particular molecular tools to implement therapeutic benefit; if successful, the research could be added to the current Synlogic technology and therefore increase its value. Based on the magnitude of Dr. Lesser’s financial interest in Synlogic and the close connection between the company’s interests and the research, the review panel determined that the financial interest could directly and significantly affect the design, conduct, or reporting of the research.
Designer Probiotics for the treatment of intestinal infection and inflammation
Project Narrative It is clear that new drug delivery platforms, such as the designer probiotics we propose here are vitally needed to enable the directed delivery of high-specificity therapeutics to sites of disease to both maximize efficacy and limit off-target side effects. To address this issue, here we propose to develop designer probiotics engineered recognize and secrete single domain antibodies (VHHs), a new class of therapeutic biomolecules with exquisite neutralizing specificity, into the intestinal lumen as a novel platform for the treatment of intestinal infection and inflammation. �
Filed on October 26, 2016.
Tell us what you know about Cammie Lesser's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Cammie Lesser filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Cammie Lesser | Massachusetts General Hospital | Conflict of Interest | Synlogic | $5,000 - $9,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.